Indeed, our previous studies have shown that FOXM1 expression predicted poor prognosis of CRC patients, and FOXM1 promoted the metastasis and chemoresistance of CRC cells [4–7]. This evidence concerns the gene FOXM1 and colorectal carcinoma.